The Competition Appeal Tribunal (CAT) has ruled to certify a £2bn legal action against Microsoft over its cloud computing and software practices. The collective action court case ...
The iPad’s milestones haven’t been limited to hardware upgrades. In 2019, Apple introduced Sidecar alongside iPadOS 13 and ...
With the 2026 NFL draft almost here, let's run through a full seven-round mock for the Jacksonville Jaguars, but with a twist ...
Canva AI 2.0 is the latest update from the user-friendly platform and comes with new and faster AI models as well as a ...
It’s time to rank the cornerbacks in this class, and there are a ton of intriguing prospects. Here’s my top 10 cornerbacks in ...
The ThinkStation P3 starts with Intel’s Core Ultra Series 2 “Arrow Lake” processors, topping out with the Core Ultra 9 285K.
Student enrollment is down, artificial intelligence (AI) challenges the norm, and the technology job market is tightening—a ...
Latest addition to the Mercedes electric portfolio is the C 400 with fully variable all-wheel drive, a wieldy 4-door coupé ...
The Aviationist on MSN
Skunk Works is looking for a U-2 pilot
Despite being one of the oldest aircraft still flying in U.S. service, the U-2 remains relevant enough for Skunk Works to ...
Set on July 4th, the show's second season tackled ICE, AI, and the other torn-from-headlines Trump-era subjects - and still ...
A mass killing by a British teenager who fatally stabbed three girls and seriously wounded 10 other people at a Taylor ...
Opinion
Spyre Therapeutics (SYRE) Is Up 32.7% After $403 Million Equity Raise On Positive Phase 2 Data
Spyre Therapeutics recently completed a US$403.0 million follow-on equity offering at US$62 per share after reporting positive 12-week Phase 2 SKYLINE data for its ulcerative colitis candidate SPY001.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results